Indian pharma stocks fell up to 3% after U.S. President Trump announced a 25% tariff on Indian imports over its trade with Russia. Concerns rose about potential inclusion of generic drugs in the tariff list. Analysts expect strategic shifts by exporters and a cautious, range-bound market reaction.
